Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $100.00 price target on the stock.
LowReport
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $100.00 price target on the stock.
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $135.00 price target on the stock.
LowReport
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $135.00 price target on the stock.
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $150.00 price target on the stock.
LowReport
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $150.00 price target on the stock.
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $128.00 price target on the stock.
MediumReport
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $128.00 price target on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: